Biliary tract cancer (BTC) is a disease entity comprising diverse epithelial tumors with features of cholangiocyte differentiation, and it includes cholangiocarcinoma (CCA) and gallbladder cancer (GBC). Depending on its anatomical location, cholangiocarcinoma is categorized as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Nearly two-thirds of patients with biliary tract cancer present with advanced disease at diagnosis and in 68-86% of resections the cancer eventually recurs either locoregionally or at a distance. Chemotherapy is the first-line therapy for advanced or recurrent BTC. With the development of next-generation sequencing (NGS)-guided molecular targeted therapy, more options are available for treatment of advanced BTC. Chemotherapy, and especially a triplet regimen based on gemcitabine/cisplatin/nab-paclitaxel, has had the most significant effect, and fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX) combined with bevacizumab is promising. Molecular targeted therapy should be based on genome sequencing and appears essential to precision medicine. Fibroblast growth factor receptor (FGFR) inhibitors and isocitrate dehydrogenase (IDH) inhibitors are promising emerging targeted therapies mainly for iCCA. Other targeted therapies such as anti-human epidermal growth factor receptor-2 (HER2) therapies, MEK inhibitors, BRAF inhibitors, and poly ADP ribose polymerase (PARP) inhibitors had tentatively displayed efficacy. Further evaluations of combination strategies in particular are needed. An immune checkpoint inhibitor (ICI) alone is less efficacious, but an ICI in addition to chemotherapy or radiotherapy has resulted in a response according to many case series. However, ICIs are still being evaluated in several ongoing studies. Combination therapies have garnered attention because of interactions between signaling pathways of carcinogenesis in BTC.
"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410286426520313990","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000410656023"}],"foaf:name":[{"@language":"en","@value":"Zhang Wei"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"@language":"en","@value":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}]},{"@id":"https://cir.nii.ac.jp/crid/1410286426520313985","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000410656024"}],"foaf:name":[{"@language":"en","@value":"Zhou Hongyuan"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"@language":"en","@value":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}]},{"@id":"https://cir.nii.ac.jp/crid/1410286426520313989","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000410656025"}],"foaf:name":[{"@language":"en","@value":"Wang Yingying"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"@language":"en","@value":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}]},{"@id":"https://cir.nii.ac.jp/crid/1410286426520313986","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000410656026"}],"foaf:name":[{"@language":"en","@value":"Zhang Zewu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"@language":"en","@value":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}]},{"@id":"https://cir.nii.ac.jp/crid/1410286426520313991","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000410656027"}],"foaf:name":[{"@language":"en","@value":"Cao Guangtai"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Cangzhou Hospital of Integrated TCM-WM Cangzhou, Hebei, China."}]},{"@id":"https://cir.nii.ac.jp/crid/1410286426520313988","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000410656028"}],"foaf:name":[{"@language":"en","@value":"Song Tianqiang"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"@language":"en","@value":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}]},{"@id":"https://cir.nii.ac.jp/crid/1410286426520313984","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000410656029"}],"foaf:name":[{"@language":"en","@value":"Zhang Ti"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"@language":"en","@value":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}]},{"@id":"https://cir.nii.ac.jp/crid/1410286426520313987","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000410656030"}],"foaf:name":[{"@language":"en","@value":"Li Qiang"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"@language":"en","@value":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"18817815"},{"@type":"EISSN","@value":"18817823"}],"prism:publicationName":[{"@language":"en","@value":"BioScience Trends"},{"@language":"ja","@value":"BioScience Trends"},{"@language":"en","@value":"BST"}],"dc:publisher":[{"@language":"en","@value":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement"},{"@language":"ja","@value":"特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会"}],"prism:publicationDate":"2020-10-31","prism:volume":"14","prism:number":"5","prism:startingPage":"328","prism:endingPage":"341"},"reviewed":"false","url":[{"@id":"https://www.jstage.jst.go.jp/article/bst/14/5/14_2020.03240/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2021266744"}],"availableAt":"2020-10-31","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=biliary%20tract%20cancer","dc:title":"biliary tract cancer"},{"@id":"https://cir.nii.ac.jp/all?q=chemotherapy","dc:title":"chemotherapy"},{"@id":"https://cir.nii.ac.jp/all?q=targeted%20therapy","dc:title":"targeted therapy"},{"@id":"https://cir.nii.ac.jp/all?q=immune%20checkpoint%20inhibitor","dc:title":"immune checkpoint inhibitor"},{"@id":"https://cir.nii.ac.jp/all?q=next-generation%20sequencing","dc:title":"next-generation sequencing"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360005519455603200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144299545472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Medical treatment for cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283690992440960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360286997031032576","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620170399360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620742088192","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620963568128","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621331169152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565166759910400","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Genomic spectra of biliary tract cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094341929088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094646416128","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095064966400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rising trends in intrahepatic cholangiocarcinoma incidence and mortality: getting at the root cause"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095065615104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095368196736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095453600768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118763167360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prediction of mismatch repair deficient biliary tract cancer: Role of morphological features and host immune response detected by routine hematoxylin‐eosin staining"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846641243851520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569319995392","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569598094208","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570189637504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"FGFR inhibitors for advanced cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570462205440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855571400752640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855571563236608","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043604545280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044139716736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from theEfficacy and safety of nivolumab for metastatic biliary tract cancer
"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469126103040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469165110528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470777955456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471035930880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471241325696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944551820672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944554032128","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Polyclonal Secondary\n FGFR2\n Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945711292160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"HER2-targeted therapies — a role beyond breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418312718592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418803862016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419263721472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420271329664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Recurrence after resection with curative intent for distal cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420913415680","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Dauerhafte Remission unter dualer HER2-Blockade mit Trastuzumab und Pertuzumab bei metastasiertem Gallenblasenkarzinom"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544421178016896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893279686528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893301096192","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893501703296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893692774656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893833514368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cholangiocarcinoma — evolving concepts and therapeutic strategies"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893947940096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nivolumab in Previously Untreated Melanoma without\n BRAF\n Mutation"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894355734912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894541859328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894672389504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895351633280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896099664000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369173329408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369413594368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369787702272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107371349947904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC)."}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844701005056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma—2 case reports and a brief review"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844827749120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845173161984","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases
"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846074622720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318341769088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318846408320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318947633280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319317808640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319430910208","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320223214208","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320257830400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320868781952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321024717184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793789527680","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793877233024","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794508732032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794966778880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795494149888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Systemic therapies for intrahepatic cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796003206528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796253132160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"HER2/neu-directed therapy for biliary tract cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268172163456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268799829504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270528128512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270729008256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inhibitor of MEK1/2, selumetinib, for biliary tract cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271265482752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gemcitabine, Cisplatin, and nab-Paclitaxel for Patients With Advanced Biliary Tract Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205737866240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The current management of cholangiocarcinoma: A comparison of current guidelines"}]},{"@id":"https://cir.nii.ac.jp/crid/1390294353086957824","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update"}]},{"@id":"https://cir.nii.ac.jp/crid/1390302845892976256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC/GS/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: A single-center retrospective cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564238081970944","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2008121659"},{"@type":"CROSSREF","@value":"10.5582/bst.2020.03240"},{"@type":"PUBMED","@value":"32830166"},{"@type":"CIA","@value":"130007935964"},{"@type":"CROSSREF","@value":"10.1002/jhbp.988_references_DOI_H5mIRNWCVRTDKl9RLxnKdszFbeX"},{"@type":"CROSSREF","@value":"10.5582/bst.2024.01286_references_DOI_H5mIRNWCVRTDKl9RLxnKdszFbeX"},{"@type":"CROSSREF","@value":"10.5582/irdr.2022.01109_references_DOI_H5mIRNWCVRTDKl9RLxnKdszFbeX"}]}